Detalhe da pesquisa
1.
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Clin Cancer Res
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630781
2.
Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.
Clin Cancer Res
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709220